“Re-educating” tumor-associated macrophages by targeting NF-κB
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The nuclear factor κB (NF-κB) signaling pathway is important in cancer-related inflammation and malignant progression. Here, we describe a new role for NF-κB in cancer in maintaining the immunosuppressive phenotype of tumor-associated macrophages (TAMs). We show that macrophages are polarized via interleukin (IL)-1R and MyD88 to an immunosuppressive “alternative” phenotype that requires IκB kinase β–mediated NF-κB activation. When NF-κB signaling is inhibited specifically in TAMs, they become cytotoxic to tumor cells and switch to a “classically” activated phenotype; IL-12high, major histocompatibility complex IIhigh, but IL-10low and arginase-1low. Targeting NF-κB signaling in TAMs also promotes regression of advanced tumors in vivo by induction of macrophage tumoricidal activity and activation of antitumor activity through IL-12–dependent NK cell recruitment. We provide a rationale for manipulating the phenotype of the abundant macrophage population already located within the tumor microenvironment; the potential to “re-educate” the tumor-promoting macrophage population may prove an effective and novel therapeutic approach for cancer that complements existing therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. IKKβ inhibition increases macrophage tumoricidal activity. (A) WT, MyD88−/−, TLR-2−/−, and TLR-4−/− or mock, IKKβDN or IKKβf/f, and IKKβΔ BMDMs were co-cultured with ID8-Luc in a modified Boyden chamber without direct cell–cell contact for 72 h. In addition, CD11b+-selected TAMs from the ascites of ID8 tumor–bearing mice were mock (TAMmock) or IKKβDN infected (TAMDN). Invasion of ID8-Luc cells was assessed by luciferase activity in the lower part of the chamber. Macrophages deleted in MyD88, IL-1R, or IKKβ significantly reduce ID8-Luc invasion (P < 0.01; t test with Welch's correction). Data are represented as mean ± SEM of n = 6. Representative data are shown from at least three independent experiments. (B) ID8 cells were co-cultured with IKKβ-targeted BMDMs or TAMs and respective control cells. Fluorescence caspase 3/7 activity was assessed after 0, 3, and 6 h. Co-culture with IKKβDN and IKKβΔ BMDMs or TAMs expressing IKKβDN (TAMDN) significantly increases caspase 3/7 activity in ID8 cells (P < 0.01; t test with Welch's correction). Data are represented as mean ± SD of n = 6. Representative data are shown from at least three independent experiments. (C) [111In]oxine release assay after a 24-h co-culture of 111In-labeled ID8 cells with mock, IKKβDN, TAMDN or IKKβf/f, and IKKβΔ macrophages. 111In-release in cell-free culture supernatants was measured after 24 h with a scintillation counter. IKKβ-targeted macrophages promote increased cytotoxicity. Data are represented as mean of n = 3. Representative data are shown from at least three independent experiments.](https://figures.cochat.ai/paper-figures/741fab83e5184295af0f590a594611ed/re-educating-tumor-associated-macrophages-by-targeting-nf-b-figure-1.jpg)
![Figure 2. IKKβ maintains the alternative phenotype of tumor-polarized macrophages. WT, mock, IKKβDN or IKKβf/f, and IKKβΔ BMDMs were co-cultured with ID8 cells for 24 h. Supernatant was collected after 24 h and analyzed for IL-10, IL-12p70, TNF-α, and NO production by ELISA. (A) Co-cultured WT macrophages express an immunosuppressive IL-10high IL-12p70low TNF-αhigh profile. However, supernatant from co-cultured IKKβ-deleted macrophages show a significant decrease in IL-10 and TNF-α (P < 0.01; t test with Welch's correction) but increase in IL-12p70 (P < 0.01; t test with Welch's correction). Data are represented as mean ± SD of n = 3. Representative data are shown from at least three independent experiments. (B) In parallel, total RNA was isolated for real-time PCR analysis of IL-12p40 and arginase-1 in co-cultured macrophages. Targeting IKKβ in macrophages switches their phenotype to an IL-12high arginase-1low NOS2high profile, consistent with an M1 phenotype. In_addition, IKKβ-targeted macrophages secrete significantly higher levels of NO, measured as nitrite by Griess assay (P < 0.01; Mann-Whitney test). Data are represented as mean ± SD of n = 3. Representative data are shown from at least four independent experiments. (C) Macrophages were co-cultured with ID8 cells, and protein extracts were prepared at the indicated time points for biochemical analysis. Expression of NF-κB p65, serine 536 phosphorylation of p65, IKKβ, Stat1, tyrosine 701 phosphorylation of Stat1 (Tyr701), and NOS2 was measured by immunoblot analysis of cell lysates using β-actin as a loading control. Representative data are shown from at least three independent experiments. (D) [111In]oxine release assay after co-culture of ID8 ovarian cancer cells with IKKβDN or IKKβΔ BMDMs. IKKβ-targeted macrophages promote increased cytotoxicity that was reversed by the addition of the selective NOS2 inhibitor 1400W. Data are represented as mean of n = 3. Representative data are shown from at least three independent experiments.](https://figures.cochat.ai/paper-figures/2ca0616e0f4f417d8bd81ac7dc101f6c/re-educating-tumor-associated-macrophages-by-targeting-nf-b-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Cloning and Characterization of Inducible Nitric Oxide Synthase from Mouse Macrophages
Xie, Q.-W., Cho, H. J., Calaycay, J., Mumford, R. A., Swiderek, K. M., Lee, T. D., Ding, A., Troso, T., & Nathan, C. (1992) · Science · doi:10.1126/science.1373522 · Cited by 1,886
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
Balkwill, F., Charles, K. A., & Mantovani, A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.013 · Cited by 1,769
Self-citationColony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.003 · Cited by 1,451
IL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018
Cited by
Items 101–200 of 802
Kaler, P., Augenlicht, L., & Klampfer, L. (2009) · Oncogene · doi:10.1038/onc.2009.247 · Cited by 270
“5A) and tumor cells have been recently shown to induce STAT1 phoshorylation on Y701 in primary macrophages (Hagemann et al., 2008).”
Jang, J.-Y., Lee, J.-K., Jeon, Y.-K., & Kim, C.-W. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-421 · Cited by 270
“NF-κB activation in macrophages within tumor microenvironment has been known to differentiate TAM to pro-tumoral and immunosuppressive M2 phenotype during the early stage of tumor development [30].”
BackgroundHelm, O., Held‐Feindt, J., Grage‐Griebenow, E., Reiling, N., Ungefroren, H., Vogel, I., Krüger, U., Becker, T., Ebsen, M., Röcken, C., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28736 · Cited by 260
Cellular and molecular pathways linking inflammation and cancer
Porta, C., Larghi, P., Rimoldi, M., Grazia Totaro, M., Allavena, P., Mantovani, A., & Sica, A. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.06.014 · Cited by 250
“A recent study has showed that NF-kB activation plays a relevant role in governing macrophages polarization during different stage of tumour development (Hagemann et al. 2008).”
Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment
Casazza, A., Di Conza, G., Wenes, M., Finisguerra, V, Deschoemaeker, S., & Mazzone, M. (2014) · Oncogene · doi:10.1038/onc.2013.121 · Cited by 243
Cancer and Inflammation: Implications for Pharmacology and Therapeutics
Balkwill, F., & Mantovani, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.312 · Cited by 249
Self-citationManiati, E., Bossard, M., Cook, N., Candido, J. B., Emami-Shahri, N., Nedospasov, S. A., Balkwill, F. R., Tuveson, D. A., & Hagemann, T. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45797 · Cited by 248
Self-citationRegulation of macrophage function in tumors: the multifaceted role of NF-κB
Hagemann, T., Biswas, S. K., Lawrence, T., Sica, A., & Lewis, C. E. (2009) · Blood · doi:10.1182/blood-2008-12-172825 · Cited by 248
Self-citationNF-kappaB: Two Sides of the Same Coin
Pires, B., Silva, R., Ferreira, G., & Abdelhay, E. (2018) · Genes · doi:10.3390/genes9010024 · Cited by 237
“Thus, NF-κB expression in the context of different signals afforded by ovarian cancer [169] or melanoma cells [172] can drive the expression of different genes.”
BackgroundInfluentialInhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy
Sun, L., Clavijo, P. E., Robbins, Y., Patel, P., Friedman, J., Greene, S., Das, R., Silvin, C., Van Waes, C., Horn, L. A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126853 · Cited by 237
Santoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., Giannini, M., Cognigni, P. D., Ferrara, G., & Battelli, N. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.007 · Cited by 237
Microglia promote colonization of brain tissue by breast cancer cells in a Wnt‐dependent way
Pukrop, T., Dehghani, F., Chuang, H., Lohaus, R., Bayanga, K., Heermann, S., Regen, T., Rossum, D. V., Klemm, F., Schulz, M., et al. (2010) · Glia · doi:10.1002/glia.21022 · Cited by 230
“M2 TAM express variable amounts of TNFa, which is known to enhance invasive- ness of epithelial cancer cells via phosphorylation of cjun N-terminal kinase (JNK) and the nuclear factor jB pathway (Hagemann et al., 2004, 2005, 2008).”
BackgroundThe role IL-1 in tumor-mediated angiogenesis
Voronov, E., Carmi, Y., & Apte, R. N. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00114 · Cited by 228
“, and Ostrand-Rosenberg, S. (2006). Inflammation induces myeloid-derived suppressor cells that facilitate tumor”
BackgroundXiao, H., Guo, Y., Li, B., Li, X., Wang, Y., Han, S., Cheng, D., & Shuai, X. (2020) · ACS Central Science · doi:10.1021/acscentsci.9b01235 · Cited by 228
Important aspects of Toll-like receptors, ligands and their signaling pathways
Chang, Z. L. (2010) · Inflammation Research · doi:10.1007/s00011-010-0208-2 · Cited by 223
High-Density Gene Expression Analysis of Tumor-Associated Macrophages from Mouse Mammary Tumors
Ojalvo, L. S., King, W., Cox, D., & Pollard, J. W. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080676 · Cited by 221
“TAMs have been shown to regulate tumor angiogenesis,(12,53,54) promote carcinoma cell motility and intravasation, promote matrix degradation,(16,58) and modify the inflammatory context of the tumor microenvironment.(22,59) Many of these tissue trophic functions of TAMs are believed to recapitulate functions of macroph…”
BackgroundZhou, Q., Peng, R.-Q., Wu, X.-J., Xia, Q., Hou, J.-H., Ding, Y., Zhou, Q.-M., Zhang, X., Pang, Z.-Z., Wan, D.-S., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-13 · Cited by 219
“Tumor-associated macrophages (TAMs) are not only abundant in epithelial cancers, but also involved in cancer progression [10-13].”
BackgroundYing, H., Kang, Y., Zhang, H., Zhao, D., Xia, J., Lu, Z., Wang, H., Xu, F., & Shi, L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402088 · Cited by 213
Role of Macrophages in Pregnancy and Related Complications
Jena, M. K., Nayak, N., Chen, K., & Nayak, N. R. (2019) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-019-00552-7 · Cited by 206
The Role of Tumor Inflammatory Microenvironment in Lung Cancer
Tan, Z., Xue, H., Sun, Y., Zhang, C., Song, Y., & Qi, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.688625 · Cited by 203
Tumor-Associated Macrophages as Target for Antitumor Therapy
Sawa-Wejksza, K., & Kandefer-Szerszeń, M. (2018) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0480-8 · Cited by 201
“Hagemann et al. (2008) showed that inhibition of NF-jB signaling in TAMs switched them into M1 macrophages, which is cytotoxic to tumor cells, and promoted regression of advanced tumors in vivo.”
BackgroundLaoui, D., Van Overmeire, E., De Baetselier, P., Van Ginderachter, J. A., & Raes, G. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00489 · Cited by 200
“Moreover, inhibition of monocyte differentiation to M2-like TAM through inhibition of NF-κB signaling, results in an M1-like phenotype and reduced tumor growth (85).”
BackgroundMacrophage Polarization Drives Granuloma Outcome during Mycobacterium tuberculosis Infection
Marino, S., Cilfone, N. A., Mattila, J. T., Linderman, J. J., Flynn, J. L., & Kirschner, D. E. (2015) · Infection and Immunity · doi:10.1128/iai.02494-14 · Cited by 191
An antiinflammatory role for IKKβ through the inhibition of “classical” macrophage activation
Fong, C. H. Y., Bebien, M., Didierlaurent, A., Nebauer, R., Hussell, T., Broide, D., Karin, M., & Lawrence, T. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080124 · Cited by 197
Self-citationTumor-Associated Macrophages Contribute to Tumor Progression in Ovarian Cancer
Colvin, E. K. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00137 · Cited by 192
“Inhibition of IKKβ, a major activator of NFκB signaling, in ovarian TAMs prevented tumor cell invasion as well as decreased TAM production of M2 immunosuppressive cytokines and increased production of M1-associated IL-12 and NOS2 (59).”
BackgroundNakanishi, Y., Nakatsuji, M., Seno, H., Ishizu, S., Akitake-Kawano, R., Kanda, K., Ueo, T., Komekado, H., Kawada, M., Minami, M., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr128 · Cited by 190
Macrophage-based cell therapies: The long and winding road
Lee, S., Kivimäe, S., Dolor, A., & Szoka, F. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.018 · Cited by 198
Downey, C. M., Aghaei, M., Schwendener, R. A., & Jirik, F. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099988 · Cited by 193
Macrophage-Induced Tumor Angiogenesis Is Regulated by the TSC2–mTOR Pathway
Chen, W., Ma, T., Shen, X.-N., Xia, X.-F., Xu, G.-D., Bai, X.-L., & Liang, T.-B. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2684 · Cited by 189
Saeed, N. M., El-Demerdash, E., Abdel-Rahman, H. M., Algandaby, M. M., Al-Abbasi, F. A., & Abdel-Naim, A. B. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.07.020 · Cited by 185
Szebeni, G. J., Vizler, C., Kitajka, K., & Puskas, L. G. (2017) · Mediators of Inflammation · doi:10.1155/2017/9294018 · Cited by 184
Varin, A., Mukhopadhyay, S., Herbein, G., & Gordon, S. (2010) · Blood · doi:10.1182/blood-2009-08-236711 · Cited by 187
Inflammatory response of macrophages in infection
Zhang, L., & Wang, C.-C. (2014) · Hepatobiliary & Pancreatic Diseases International · doi:10.1016/s1499-3872(14)60024-2 · Cited by 189
Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska, J. G., Shen, J., & Larionova, I. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01232-z · Cited by 201
“The NFkappaB pathway was one of the fi rst suggested targets for re-education of tumor-promoting TAMs, and promising results were generated in murine cancer models [278].”
Macrophages Associated with Tumors as Potential Targets and Therapeutic Intermediates
Vinogradov, S., Warren, G., & Wei, X. (2014) · Nanomedicine · doi:10.2217/nnm.14.13 · Cited by 182
MicroRNA-mediated control of macrophages and its implications for cancer
Squadrito, M. L., Etzrodt, M., De Palma, M., & Pittet, M. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.02.003 · Cited by 187
NLRP3 Suppresses NK Cell–Mediated Responses to Carcinogen-Induced Tumors and Metastases
Chow, M. T., Sceneay, J., Paget, C., Wong, C. S. F., Duret, H., Tschopp, J., Möller, A., & Smyth, M. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0509 · Cited by 182
“signaling pathway has been shown to be critical in the polarization of macrophages towards an immunosuppressive M2 phenotype (45).”
BackgroundContribution of adipose tissue to development of cancer
Cozzo, A. J., Fuller, A. M., & Makowski, L. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c170008 · Cited by 188
“In fact, NF-κ B signaling is a known mediator of the tumor promoting activities of both early-stage, proinflammatory TAMs, and late-stage immunosuppressive TAMs (45,155,156,293).”
De Palma, M., & Hanahan, D. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.011 · Cited by 183
“…the development of more effective, fully personalized cancer therapies, that for example target the inflammatory component of the tumor by reprogramming leukocyte infiltrates from a tumor-promoting to an anti-tumor function (Hagemann et al., 2008; Squadrito and De Palma, 2011; Stout et al., 2009).”
BackgroundTan, Y., Sun, R., Liu, L., Yang, D., Xiang, Q., Li, L., Tang, J., Qiu, Z., Peng, W., Wang, Y., et al. (2021) · Theranostics · doi:10.7150/thno.58322 · Cited by 176
“TAK1, also known as Mitogen-Activated Protein Kinase Kinase Kinase 7, is a member of the MAPKKK family, and mediates the phosphorylation of IKKα and IKKβ [19, 20].”
BackgroundInfluentialMolecular pathways and targets in cancer-related inflammation
Mantovani, A., Garlanda, C., & Allavena, P. (2010) · Annals of Medicine · doi:10.3109/07853890903405753 · Cited by 185
Wilcox, R. A., Wada, D. A., Ziesmer, S. C., Elsawa, S. F., Comfere, N. I., Dietz, A. B., Novak, A. J., Witzig, T. E., Feldman, A. L., Pittelkow, M. R., et al. (2009) · Blood · doi:10.1182/blood-2009-05-220111 · Cited by 170
Tumor‐associated macrophages (TAMs) depend on ZEB1 for their cancer‐promoting roles
Cortés, M., Sanchez‐Moral, L., de Barrios, O., Fernández‐Aceñero, M. J., Martínez‐Campanario, M., Esteve‐Codina, A., Darling, D. S., Győrffy, B., Lawrence, T., Dean, D. C., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201797345 · Cited by 174
“Intraperitoneal injection of ID8 ovarian carcinoma cells into female recipient mice results in their rapid growth and the development of ascites with abundant by TAMs (Hagemann et al , 2006, 2008; Yin et al , 2016).”
InfluentialSelf-citationTakaishi, K., Komohara, Y., Tashiro, H., Ohtake, H., Nakagawa, T., Katabuchi, H., & Takeya, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01652.x · Cited by 170
Macrophage regulation of tumor angiogenesis: Implications for cancer therapy
Squadrito, M. L., & De Palma, M. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.005 · Cited by 170
Tumour-associated macrophages and cancer
Cook, J., & Hagemann, T. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.05.017 · Cited by 165
“This resulted in a reduced tumour volume compared to non-targeted macrophages [63].”
BackgroundSelf-citationLeopold Wager, C. M., & Wormley, F. L. (2014) · Mucosal Immunology · doi:10.1038/mi.2014.65 · Cited by 172
Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy
Huang, Z., Zhang, Z., Jiang, Y., Zhang, D., Chen, J., Dong, L., & Zhang, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.013 · Cited by 169
Sprinzl, M. F., Reisinger, F., Puschnik, A., Ringelhan, M., Ackermann, K., Hartmann, D., Schiemann, M., Weinmann, A., Galle, P. R., Schuchmann, M., et al. (2013) · Hepatology · doi:10.1002/hep.26328 · Cited by 169
“This may include the polarization of TAM, as inhibition of NF-jB in TAM has been reported to induce antitumoral immune responses.(23) Sorafenib targets, such as the CSF-receptor-1,(24) MAPKp38,(12) and JAK/ STAT,(25) which are pivotal for MU maturation, support this finding.”
ResultWerno, C., Menrad, H., Weigert, A., Dehne, N., Goerdt, S., Schledzewski, K., Kzhyshkowska, J., & Brune, B. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq088 · Cited by 167
“Re-programming TAMs towards M1 restores their tumoricidal capacity, which reduces tumor growth [34].”
BackgroundSun, L., Chen, B., Jiang, R., Li, J., & Wang, B. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2016.11.002 · Cited by 159
O'Brien, J., Martinson, H., Durand-Rougely, C., & Schedin, P. (2012) · Development · doi:10.1242/dev.071696 · Cited by 162
“An alternative strategy involves re-educating tumor-promoting macrophages to become tumor suppressive (Gordon and Taylor, 2005; Hagemann et al., 2008).”
BackgroundNF-κB as a central regulator of macrophage function in tumors
Biswas, S. K., & Lewis, C. E. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0310153 · Cited by 161
Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer
Kubala, M. H., Punj, V., Placencio-Hickok, V. R., Fang, H., Fernandez, G. E., Sposto, R., & DeClerck, Y. A. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.082 · Cited by 162
“PAI-1 expression is correlated with CD163 expression in human cancers Supporting a link between PAI-1 and TAM polarization, an analysis of RNA-seq data from The Cancer Genome Atlas (TCGA) and gene expression array data from the Gene Expression Omnibus (GEO) database for PAI-1 and CD163 (an M2 marker) expression reveal…”
BackgroundInfluentialHPV16 Tumor Associated Macrophages Suppress Antitumor T Cell Responses
Lepique, A. P., Daghastanli, K. R. P., Cuccovia, I. M., & Villa, L. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0489 · Cited by 159
Zhan, X., Jia, L., Niu, Y., Qi, H., Chen, X., Zhang, Q., Zhang, J., Wang, Y., Dong, L., & Wang, C. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.09.007 · Cited by 161
Tan, H.-Y., Wang, N., Man, K., Tsao, S.-W., Che, C.-M., & Feng, Y. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.271 · Cited by 154
Macrophage-Specific RNA Interference Targeting via “Click”, Mannosylated Polymeric Micelles
Yu, S. S., Lau, C. M., Barham, W. J., Onishko, H. M., Nelson, C. E., Li, H., Smith, C. A., Yull, F. E., Duvall, C. L., & Giorgio, T. D. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300434e · Cited by 166
A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis
Zaynagetdinov, R., Sherrill, T. P., Polosukhin, V. V., Han, W., Ausborn, J. A., McLoed, A. G., McMahon, F. B., Gleaves, L. A., Degryse, A. L., Stathopoulos, G. T., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100558 · Cited by 147
Targeting Tumor-Infiltrating Macrophages to Combat Cancer
Panni, R. Z., Linehan, D. C., & DeNardo, D. G. (2013) · Immunotherapy · doi:10.2217/imt.13.102 · Cited by 152
Santoni, M., Massari, F., Amantini, C., Nabissi, M., Maines, F., Burattini, L., Berardi, R., Santoni, G., Montironi, R., Tortora, G., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1487-6 · Cited by 161
“[83] have observed that the inhibition of IκB kinase (IKK)β, the major activator of NFκB, reversed TAM tumor-promoting activity and promoted the switch to M1 phenotype.”
BackgroundLança, T., & Silva-Santos, B. (2012) · OncoImmunology · doi:10.4161/onci.20068 · Cited by 149
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 151
“Inhibition of NFκB allows TAMs to acquire a tumoricidal phenotype, resulting in vivo in regression of advanced tumors (219).”
BackgroundNuclear Factor-κB and Tumor-Associated Macrophages
Mancino, A., & Lawrence, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1015 · Cited by 149
“Targeting IKKβ in TAM (13) and macrophages during infection (28) also associated with increased activation of STAT-1, which is critical for IL-12, NOS2, and MHC II expression (Fig.”
BackgroundSelf-citationNF-κB signaling pathway in tumor microenvironment
Cao, Y., Yi, Y., Han, C., & Shi, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476030 · Cited by 169
“In 2008, Thorsten Hagemann and colleagues demonstrated that the depletion of IKK-b activity within TAMs can revert their tumor-promoting phenotype to antitumor M1 phenotype, indicating that reprogramming TAMs by target IKK-b target to eliminate tumor cells (44).”
BackgroundFridlender, Z. G., Kapoor, V., Buchlis, G., Cheng, G., Sun, J., Wang, L.-C. S., Singhal, S., Snyder, L. A., & Albelda, S. M. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0080oc · Cited by 147
“However, TAMs can be redirected from an M2 to a non-M2 phenotype, for example, by blocking NF-kB activity (40) or that of other macrophage-activating agents (34, 39), and enhanced antitumor activity may thus be achieved.”
BackgroundIκB kinase regulation of the TPL‐2/ERK MAPK pathway
Gantke, T., Sriskantharajah, S., Sadowski, M. I., & Ley, S. C. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01104.x · Cited by 158
Valilou, S. F., Keshavarz‐Fathi, M., Silvestris, N., Argentiero, A., & Rezaei, N. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.01.007 · Cited by 158
Xu, M., Liu, M., Du, X., Li, S., Li, H., Li, X., Li, Y., Wang, Y., Qin, Z., Fu, Y.-X., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402603 · Cited by 141
“, LPS and IFN-g) drives macrophages toward a classic (M1) activation state characterized by proinflammatory activity, tumoricidal function, and the promotion of T cell responses (21, 22).”
BackgroundThe NF-κB/AKT-dependent Induction of Wnt Signaling in Colon Cancer Cells by Macrophages and IL-1β
Kaler, P., Godasi, B. N., Augenlicht, L. H., & Klampfer, L. (2009) · Cancer Microenvironment · doi:10.1007/s12307-009-0030-y · Cited by 166
“Malignant cells have been shown to drive NF-κB activation in TAMs in order to maintain their immunosuppressive phenotype [ 47 ], suggesting that intact NF-κB signaling in both tumor cells and macrophages is required for the interaction of tumor cells with tumor associated macrophages.”
BackgroundRegulation of NK Cell Function by Human Granulocyte Arginase
Oberlies, J., Watzl, C., Giese, T., Luckner, C., Kropf, P., Müller, I., Ho, A. D., & Munder, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803523 · Cited by 139
Mukhtar, R. A., Nseyo, O., Campbell, M. J., & Esserman, L. J. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.97 · Cited by 140
Mechanisms and Targets Involved in Dissemination of Ovarian Cancer
Weidle, U. H., Birzele, F., Kollmorgen, G., & Rueger, R. (2016) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20004 · Cited by 154
Targeting signaling factors for degradation, an emerging mechanism for TRAF functions
Yang, X., & Sun, S. (2015) · Immunological Reviews · doi:10.1111/imr.12311 · Cited by 137
Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients
Piersma, S. J. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0066-7 · Cited by 150
“studies described that skewing of the phenotype towards a proinflammatory M1 phenotype by inhibition of IKKβ results in improved tumoricidal activity [181, 182].”
BackgroundPrescott, J. A., & Cook, S. J. (2018) · Cells · doi:10.3390/cells7090115 · Cited by 139
Mylonas, K. J., Nair, M. G., Prieto-Lafuente, L., Paape, D., & Allen, J. E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803463 · Cited by 140
The role of β3-integrins in tumor angiogenesis: context is everything
Robinson, S. D., & Hodivala‐Dilke, K. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.03.014 · Cited by 150
Self-citationChen, X.-J., Deng, Y.-R., Wang, Z., Wei, W.-F., Zhou, C.-F., Zhang, Y., Yan, R.-M., Liang, L.-J., Zhong, M., Li, L., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1748-1 · Cited by 145
NF-κB Signaling in Ovarian Cancer
Harrington, B. S., & Annunziata, C. M. (2019) · Cancers · doi:10.3390/cancers11081182 · Cited by 153
“In a co-culture experiment of mouse bone-marrow-derived macrophages (BMDMs) with mouse ovarian cancer cell line ID-8, the importance of upstream activators of canonical NF-κB signaling was demonstrated by specific knockouts of Myd-88, IL1R, TLR2 and TLR4 in the BMDMs, which caused decreased invasion of ID-8 cells in v…”
BackgroundInfluentialJu, S., Ge, Y., Li, P., Tian, X., Wang, H., Zheng, X., & Ju, S. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1387701 · Cited by 142
Meli, R., Mattace Raso, G., & Calignano, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00177 · Cited by 137
“Conversely, adiponectin was recently shown to shift KC polarization to the M2/anti-inflammatory phenotype (44, 45), preventing progression of NASH in mice (46).”
BackgroundThe Role of Exosomes in Breast Cancer
Lowry, M. C., Gallagher, W. M., & O’Driscoll, L. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.240028 · Cited by 151
Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies
Quail, D. F., & Joyce, J. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0133 · Cited by 135
“However, as discussed here, rather than depleting macrophages, reprogramming or alteringmobilization of progenitor cellsmight result in improved disease outcomes (16, 63, 67).”
BackgroundHuang, Z. D., Yang, Y., Jiang, Y., Shao, J., Sun, X., Chen, J., Dong, L., & Zhang, J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.062 · Cited by 140
Targeting tumor associated macrophages: The new challenge for nanomedicine
Andón, F. T., Digifico, E., Maeda, A., Erreni, M., Mantovani, A., Alonso, M. J., & Allavena, P. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.004 · Cited by 136
Mehraj, U., Ganai, R. A., Macha, M. A., Hamid, A., Zargar, M. A., Bhat, A. A., Nasser, M. W., Haris, M., Batra, S. K., Alshehri, B., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00634-9 · Cited by 143
ROS: A “booster” for chronic inflammation and tumor metastasis
Chen, A., Huang, H., Fang, S., & Hang, Q. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189175 · Cited by 151
The role of chemokines and their receptors in angiogenesis
Kiefer, F., & Siekmann, A. F. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0677-7 · Cited by 143
“The first results obtained by blockade of the NFjB pathway in a mouse model of ovarian cancer are promising [143].”
BackgroundTumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy
Baay, M. F. D., Brouwer, A., Pauwels, P., Peeters, M., & Lardon, F. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/565187 · Cited by 142
Development of individualized anti-metastasis strategies by engineering nanomedicines
He, Q., Guo, S., Qian, Z., & Chen, X. S. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00511b · Cited by 133
Yu, Z., Li, Y., Li, Y., Zhang, J., Li, M., Ji, L., Tang, Y., Zheng, Y., Sheng, J., Han, Q., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004297 · Cited by 129
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression.
Koelwyn, G. J., Wennerberg, E., Demaria, S., & Jones, L. W. (2015) · PubMed · Cited by 162
Transcriptional, Epigenetic and Metabolic Programming of Tumor-Associated Macrophages
Larionova, I., Kazakova, E., Patysheva, M. R., & Kzhyshkowska, J. G. (2020) · Cancers · doi:10.3390/cancers12061411 · Cited by 138
“IL-17 promotes THP-1 cell differentiation towards M2-like phenotype (characterized by increased expression of CD163 and CD206, TGF-β, VEGF and IL-10 production) through NF-κB signaling pathway [47] (Table 1).”
BackgroundInfluentialThe good and the bad of chemokines/chemokine receptors in melanoma
Richmond, A. J., Yang, J., & Su, Y. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00554.x · Cited by 136
“There are two types of TAMs, M1 and M2 (Hagemann et al., 2008).”
BackgroundMicroenvironment-Derived IL-1 and IL-17 Interact in the Control of Lung Metastasis
Carmi, Y., Rinott, G., Dotan, S., Elkabets, M., Rider, P., Voronov, E., & Apte, R. N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002901 · Cited by 115
Tumor-associated macrophages and anti-tumor therapies: complex links
Belgiovine, C., D’Incalci, M., Allavena, P., & Frapolli, R. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2166-5 · Cited by 137
Cancer Metabolism Drives a Stromal Regenerative Response
Schwörer, S., Vardhana, S. A., & Thompson, C. B. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.015 · Cited by 123
“Of note, the environment of a tumor is reminiscent of a healing wound, where a variety of distinct cell types, including fibroblasts as well as immune cells, play a coordinated role in tissue regeneration (Dvorak, 2015; Hagemann et al., 2008) (Figures 1 and 2).”
BackgroundTreps, L., Faure, S., & Clere, N. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107805 · Cited by 135
Wang, S., Yan, W., Kong, L., Zuo, S., Wu, J., Zhu, C., Huang, H., He, B., Dong, J., & Wei, J. (2023) · Nature Communications · doi:10.1038/s41467-023-39683-z · Cited by 132
Metadata
- Authors
- Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R.
- Affiliations
- Queen Mary University of London (GB)
- 1Centre for Cancer and Inflammation
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2008-05-19
- Volume
- 205
- Issue
- 6
- Pages
- 1261-1268
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2413024
- OpenAlex
- W2105724560
- Cited by
- 792
- References
- 25
- Citations by year
- 2026: 12 · 2025: 22 · 2024: 32 · 2023: 28 · 2022: 42 · 2021: 41 · 2020: 45 · 2019: 31 · 2018: 50 · 2017: 49 · 2016: 49 · 2015: 46 · 2014: 73 · 2013: 64 · 2012: 41
- FWCI
- 23.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- tumor-associated macrophages, NF-κB signaling, macrophage polarization, alternative macrophage activation, IκB kinase β, MyD88, interleukin-1 receptor, IL-12, NK cell recruitment, tumor immunosuppression, tumor microenvironment, antitumor immunity, tumor regression
- MeSH terms
- Animals, Cell Differentiation, Humans, Immunosuppression Therapy, Macrophages, Neoplasms, Phenotype, Signal Transduction, NF-kappa B, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.